imatinib mesylate has been researched along with Weight Loss in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Acharya, MR; Goel, M; Nadkarni, S; Parray, A; Patel, S; Patkar, S; Shah, A | 1 |
| Begna, K; Smith, CJ; Stewart, G | 1 |
| Ceelen, W; De Wever, O; Descamps, B; Gremonprez, F; Izmer, A; Vanhaecke, F; Vanhove, C | 1 |
| Azouz, MM; Bouassida, M; Chelbi, E; El Bouchtili, S; Ezzine, H; Hamzaoui, L; Mahmoudi, M; Medhioub, M; Touinsi, H | 1 |
| Fu, D; Jin, C; Ni, Q; Yang, F | 1 |
| Cleris, L; Formelli, F; Gambacorti-Passerini, C; Pilotti, S; Puttini, M; Ruchatz, H | 1 |
| Blyweert, W; De Ridder, D; Debiec-Rychter, M; Ost, D; Sciot, R; Van der Aa, F; Van Oosterom, A; Van Poppel, H | 1 |
1 review(s) available for imatinib mesylate and Weight Loss
| Article | Year |
|---|---|
Extra-gastrointestinal stromal tumor of the pancreas: clinical characteristics, diagnosis, treatment, and outcome.
Topics: Abdominal Pain; Antineoplastic Agents; Benzamides; Fatigue; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Middle Aged; Pancreatectomy; Pancreatic Neoplasms; Piperazines; Pyrimidines; Splenectomy; Weight Loss | 2011 |
6 other study(ies) available for imatinib mesylate and Weight Loss
| Article | Year |
|---|---|
Primary Hepatic Gastrointestinal Stromal Tumour (GIST): Unusual Presentation and Diagnosis.
Topics: Aged; Anorexia; Chemotherapy, Adjuvant; Female; Gastrointestinal Stromal Tumors; Hepatectomy; Humans; Imatinib Mesylate; Liver; Liver Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Weight Loss | 2020 |
44-Year-Old Man With Fatigue, Weight Loss, and Leukocytosis.
Topics: Adult; Basophils; Diagnosis, Differential; Exercise Tolerance; Fatigue; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Leukocytosis; Male; Protein Kinase Inhibitors; Treatment Outcome; Weight Loss | 2021 |
Pretreatment with VEGF(R)-inhibitors reduces interstitial fluid pressure, increases intraperitoneal chemotherapy drug penetration, and impedes tumor growth in a mouse colorectal carcinomatosis model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colorectal Neoplasms; Extracellular Fluid; HT29 Cells; Humans; Imatinib Mesylate; Indazoles; Infusions, Parenteral; Mice; Neovascularization, Pathologic; Organoplatinum Compounds; Oxaliplatin; Peritoneal Absorption; Peritoneum; Pressure; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Tumor Burden; Weight Loss; Xenograft Model Antitumor Assays | 2015 |
Gastrointestinal stromal tumours (GISTs): A descriptive study on 29 cases.
Topics: Abdominal Pain; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Intestinal Neoplasms; Intestine, Small; Male; Middle Aged; Proto-Oncogene Proteins c-kit; Pyrroles; Retrospective Studies; Stomach Neoplasms; Sunitinib; Survival Rate; Tumor Burden; Weight Loss | 2016 |
Effect of imatinib on haematopoietic recovery following idarubicin exposure.
Topics: Animals; Antineoplastic Agents; Benzamides; Body Weight; Bone Marrow; Drug Administration Schedule; Female; Hematopoiesis; Hematopoietic Stem Cells; Idarubicin; Imatinib Mesylate; Mice; Mice, Nude; Piperazines; Pyrimidines; Spleen; Weight Loss | 2003 |
Gastrointestinal stromal tumor of the prostate.
Topics: Acute Disease; Amino Acid Substitution; Antineoplastic Agents; Benzamides; Humans; Imatinib Mesylate; Liver Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Proteins; Piperazines; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Radiography; Sarcoma; Urinary Retention; Weight Loss | 2005 |